Medical News: ECCO-ESMO: Bevacizumab Safe in 'Real World'

Action Points

---

• Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  



• Explain that a retrospective study showed a benefit for bevacizumab in patients with recurrent ovarian cancer, similar to benefits seen in prior clinical trials.
  



• Note that the greatest benefit from bevacizumab was seen in platinum-sensitive ovarian cancer and those receiving second- or third-line treatment in combination with chemotherapy.